(Q38202024)

30 August 2017

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma (English)

1 reference

multiple endocrine neoplasia type 2

30 August 2017

1 reference

1 reference

2

Jeffrey A Norton

1 reference

30 August 2017

Geoffrey W Krampitz

1

1 reference

PubMed ID

24699901

30 August 2017

language of work or name

English

0 references

publication date

3 April 2014

1 reference

30 August 2017

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

30 August 2017

120

1 reference

30 August 2017

13

1 reference

30 August 2017

1920-1931

1 reference

Multiple endocrine neoplasia type 2: an overview

30 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Evidence of MEN-2 in the original description of classic pheochromocytoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Multiple endocrine neoplasia type 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Multiple Endocrine Neoplasia Type IIb: The Most Aggressive Form of Medullary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Activation of a novel human transforming gene, ret, by DNA rearrangement

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

GDNF signalling through the Ret receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The GDNF-RET signalling partnership

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Functional receptor for GDNF encoded by the c-ret proto-oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Targeting the RET pathway in thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET signaling is required for survival and normal function of nonpeptidergic nociceptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Protein kinase A regulates GDNF/RET-dependent but not GDNF/Ret-independent ureteric bud outgrowth from the Wolffian duct

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

SOX9 controls epithelial branching by activating RET effector genes during kidney development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Neurturin-mediated ret activation is required for retinal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET-deficient mice: an animal model for Hirschsprung's disease and renal agenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Mutations of the RET proto-oncogene in Hirschsprung's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET and GDNF mutations are rare in fetuses with renal agenesis or other severe kidney development defects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The many faces of RET dysfunction in kidney

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Renal aplasia in humans is associated with RET mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Calcitonin-a hormone from the parathyroid which lowers the calcium-level of the blood

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

THYROCALCITONIN: HYPOCALCEMIC HYPOPHOSPHATEMIC PRINCIPLE OF THE THYROID GLAND

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Early Diagnosis of Medullary Carcinoma of the Thyroid Gland by Means of Calcitonin Assay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Update multiple endocrine neoplasia type 2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Medullary thyroid cancer: management guidelines of the American Thyroid Association

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Early Malignant Progression of Hereditary Medullary Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

New developments in thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Cabozantinib in progressive medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Current management of medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A Novel Germ-Line Point Mutation in RET Exon 8 (Gly533Cys) in a Large Kindred with Familial Medullary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Primary hyperparathyroidism in multiple endocrine neoplasia type 2A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Novel germline RET mutation segregating with papillary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The Y606C RET mutation causes a receptor gain of function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Germline mutation of RET codon 883 in two cases of de novo MEN 2B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28661

7 January 2021

Identifiers

DOI

10.1002/CNCR.28661

1 reference

30 August 2017

1 reference

PubMed ID

24699901